secwatch / observer
8-K filed May 15, 2026, 4:46 PM ET ticker PSTV CIK 0001095981
other confidence high sentiment neutral materiality 0.25

Plus Therapeutics holds annual meeting post 1-for-25 reverse split; all proposals pass

PLUS THERAPEUTICS, INC.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.98

PLUS THERAPEUTICS, INC. shareholders approved Sixth Amendment and Restatement of the Company’s 2020 Stock Incentive Plan at the 2026-05-14 meeting.

Proposal
equity plan
Outcome
passed
Meeting
2026-05-14
Exact text from the filing
Proposal No. 4 – Sixth Amendment and Restatement of the Company’s 2020 Stock Incentive Plan. The Company’s stockholders approved the sixth amendment and restatement of the Company’s 2020 Stock Incentive Plan. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,976,002 5,648,887 425,414 50,807,018
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.98

PLUS THERAPEUTICS, INC. shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-05-14 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-05-14
Exact text from the filing
Proposal No. 3 - Advisory Vote on the Compensation of Named Executive Officers. The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,389,498 3,364,694 296,111 50,807,018
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.98

PLUS THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-14 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-05-14
Exact text from the filing
Proposal No. 2 - Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the appointment of CBIZ CPAs, P.C. as the Company’s independent registered public accounting firm for the 2026 fiscal year. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 60,860,051 2,292,062 1,705,208 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

PLUS THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-05-14 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-05-14
Exact text from the filing
Proposal No. 1 - Election of Directors. The Company's stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for a term expiring at the Company’s Annual Meeting of Stockholders in 2027 and until each such person’s successors is duly elected and qualified, or until his or her earlier death, resignation or removal: Votes For Votes Withheld Broker Non-Votes Howard Clowes 11,863,579 2,186,724 50,807,018 An van Es-Johansson, M.D. 12,384,866 1,665,437 50,807,018 Richard J. Hawkins 12,344,152 1,706,151 50,807,018 Marc H. Hedrick, M.D. 12,350,511 1,699,792 50,807,018 Ronald A. Andrews 12,417,138 1,633,165 50,807,018 Kyle Guse, Esq., MBA, CPA 12,384,591 1,665,712 50,807,018
View on SEC.gov

461 shareholder votes filed in the last 30 days. Browse all shareholder votes →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR
accession 0001193125-26-227059
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.